n-3 Fatty Acid Infusion and Type 2 Diabetes

NACompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

January 31, 2004

Primary Completion Date

May 31, 2004

Study Completion Date

October 31, 2008

Conditions
Type 2 Diabetes
Interventions
DIETARY_SUPPLEMENT

Intralipid +/- Omegaven

"Intralipid®: the 500 ml 20% Intralipid will be infused during a hyperinsulinemic clamp. Infusion rate will increase from 50 to 100 ml/hour the first 30 min and then continue at 100 ml/hour for the next 210 min, infusion duration 240 min (4 hours) in all.~Intralipid® + Omegaven®: In the 500 ml 20% Intralipid 100 ml will be replaced by 100 ml 10% Omegaven and infused during the hyperinsulinemic clamp as described for Intralipid only. Heparin (0.4 U/kg/min) will be added to both lipid emulsions.~Content of marine n-3 fatty acids in 100 ml Omegaven will be 1.25-2.82 g EPA and 1.44-3.09 g DHA (seasoning variations of n-3 fatty acids in fish oil)."

Trial Locations (1)

N-7006

Department of Medicine, Division of Endocrinology, St. Olavs Hospital, Trondheim

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Norwegian University of Science and Technology

OTHER

collaborator

Norwegian Foundation for Health and Rehabilitation

OTHER

collaborator

Novo Nordisk A/S

INDUSTRY

collaborator

Norwegian Diabetes Association

OTHER

lead

St. Olavs Hospital

OTHER